FDA's perspective on rapid review for AIDS drugs

FDA's perspective on rapid review for AIDS drugs

WASHINGTON - FDA officials, including Commissioner David Kessler and David Feigal, director of the antiviral drug products division, reaffirmed the agency's commitment to rapid approval of AIDS drugs and provided some clues about the future course of accelerated review at a day-and-a-half-long meeting of the Antiviral Drugs Advisory Committee last week.

Outlining the FDA's requirements for AIDS trials, Feigal said,

Read the full 675 word article

How to gain access

Continue reading with a
two-week free trial.